Welcome to the DDRiver™ Clinical Trials Program

If you are an HCP, click on “I’m a Healthcare Professional"

If you are a patient, please click on “I’m not a Healthcare Professional”

Leaving DDRiver™ website

You are leaving DDRiver™ Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. EMD Serono does not control the content of these websites.

Investigating DNA Damage Response (DDR) Inhibition in Multiple Tumor Types

The purpose of this website is to provide information to healthcare professionals about clinical trials for agents targeting the DDR pathway in various types of cancers.

These clinical trials are sponsored by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada.


Our Program

Welcome to the DDRiver™ Clinical Trials Program—a program investigating the anticancer effect of inhibiting the DDR pathway in multiple tumor types.

Several DDR inhibitors are under clinical investigation and have not yet been proven to be safe and effective. There is no guarantee that any compound will be approved in the sought-after indication by any health authority.

Group mask 3

Learn More About Our Science

Many cancers have defects in DDR proteins and pathways that may render cells more susceptible to DNA damage and to inhibitors of the DDR pathway.1,2


1. Zenke FT, et al. Mol Cancer Ther. 2020;19(5):1091-1101; 2. Zimmermann A, et al. Mol Cancer Ther. 2022;21(6):859-870.